|
2,923
|
| 26778 |
Reactive oxygen species
|
|
increases_quantity of
|
Vcam1
|
in vascular endothelial cell (PECAM1)
|
in vivo
|
|
19797522
|
|
2,944
|
| 26851 |
response to hypoxia
|
|
decreases_quantity of
|
Reactive oxygen species
|
|
|
| 26855 |
response to hypoxia
|
|
increases_expression of
|
Vegfa
|
by increasing the expression of the transcription factorm Hif1a
|
|
| 26856 |
response to hypoxia
|
|
increases_expression of
|
Pgk1
|
|
|
| 26858 |
response to hypoxia
|
|
increases_expression of
|
Hk2
|
|
|
| 26870 |
HSC (CD34-KSL)
|
|
increases_expression of
|
Vegfa
|
compared to more differentiated BM cells (CD34+KSL)
|
|
| 26871 |
HSC (CD34+KSL)
|
|
decreases_expression of
|
Vegfa
|
compared to primitive HSC (CD34-KSL)
|
|
| 26874 |
response to hypoxia
|
|
increases_activity of
|
repopulation >16 weeks
|
of HSC (CD34-KSL) via hypoxia/HIF-driven Vegfa up-regulation
|
|
| 36293 |
response to hypoxia
|
|
decreases_activity of
|
response to oxidative stress
|
|
|
|
21670467
|
|
3,395
|
| 31552 |
response to hypoxia
|
|
increases_quantity of
|
Hif1a
|
by inhibiting polyubiquitination and subsequent proteasomal degradation of HIF-alpha subunits
|
|
| 31554 |
Hif1a
|
|
increases_expression of
|
Vegfa
|
by binding to hypoxia-response elements (HRE)
|
|
| 31556 |
Hif1a
|
|
increases_expression of
|
Epo
|
by binding to hypoxia-response elements (HRE)
|
|
| 31558 |
Hif1a
|
|
interacts (colocalizes) with
|
Arnt
|
|
|
| 31560 |
Csf3
|
|
increases_activity of
|
response to hypoxia
|
|
in vivo
|
| 31562 |
Csf3
|
|
increases_quantity of
|
Hif1a
|
|
in vivo
|
| 31563 |
response to hypoxia
|
|
increases_quantity of
|
Hif1a
|
|
in vivo
|
|
17478585
|
|
3,635
|
| 34467 |
Foxo3
|
|
decreases_quantity of
|
Reactive oxygen species
|
in HSC (KSL)
|
in vivo
|
| 34468 |
Foxo3
|
|
increases_expression of
|
Sod2
|
in HSC (CD34-KSL) cells
|
|
| 34470 |
Foxo3
|
|
increases_expression of
|
Cat
|
in HSC (CD34-KSL) cells
|
|
| 34471 |
HSC (CD34-KSL)
|
|
increases_expression of
|
Sod2
|
|
|
| 34472 |
HSC (CD34-KSL)
|
|
increases_expression of
|
Cat
|
|
|
| 34473 |
Sod2
|
|
decreases_quantity of
|
Reactive oxygen species
|
|
|
| 34474 |
Cat
|
|
decreases_quantity of
|
Reactive oxygen species
|
|
|
| 36292 |
Foxo3
|
|
decreases_activity of
|
response to oxidative stress
|
in HSC (KSL)
|
in vivo
|
|
18371339
|
|
3,640
|
| 34484 |
Reactive oxygen species
|
|
decreases_activity of
|
repopulation >16 weeks
|
of HSC (KSL)
|
in vivo
|
| 34499 |
Reactive oxygen species
|
|
increases_expression of
|
Cdkn2a
|
in HSC (KSL), but not in differentiated Lin+ cells
|
in vitro
|
| 34502 |
Reactive oxygen species
|
|
increases_expression of
|
Cdkn2a
|
in HSC (CD34-KSL), but not in differentiated Lin+ cells
|
in vitro
|
| 34506 |
Reactive oxygen species
|
|
increases_activity of
|
Mapk14
|
in HSC (CD34-KSL), but not in differentiated Lin+ cells
|
in vitro
|
| 34512 |
Atm
|
|
decreases_quantity of
|
Reactive oxygen species
|
in HSC (KSL)
|
in vivo
|
| 34555 |
aging
|
|
increases_quantity of
|
Reactive oxygen species
|
in HSC (KSL); ROS levels also increased during serial transplantation.
|
in vivo
|
| 34563 |
Reactive oxygen species
|
|
decreases_activity of
|
self-renewal
|
in HSC (KSL)
|
in vivo
|
| 34564 |
Reactive oxygen species
|
|
decreases_activity of
|
quiescence
|
in HSC (KSL); by activating p38MAPK (Mapk14).
|
in vivo
|
|
16565722
|
|
3,650
|
| 34650 |
Tdgf1
|
|
interacts (colocalizes) with
|
Hspa5
|
|
in vivo
|
| 34758 |
response to hypoxia
|
|
increases_expression of
|
Tdgf1
|
|
|
| 34760 |
Hif1a
|
|
increases_expression of
|
Tdgf1
|
under hypoxic conditions
|
|
| 34761 |
Hif1a
|
|
increases_quantity of
|
osteoblast-enriched cell (Alcam+Sca1-)
|
|
in vivo
|
| 34762 |
Hif1a
|
|
increases_quantity of
|
primary MSC-enriched cell (Alcam-Sca1+)
|
|
in vivo
|
| 34763 |
Hif1a
|
|
increases_expression of
|
Tdgf1
|
|
|
|
21982233
|
|
3,664
|
| 35041 |
Vhl
|
|
decreases_quantity of
|
Hif1a
|
by proteasomal degradation of hydroxylated Hif1alpha
|
|
| 35042 |
response to hypoxia
|
|
increases_quantity of
|
Hif1a
|
by inhibiting hydroxylation and subsequent proteasomal degradation of Hif1alpha
|
|
| 35046 |
Kitl
|
|
increases_quantity of
|
Hif1a
|
by stabilising Hif1alpha even under normoxic conditions
|
|
| 35049 |
Thpo
|
|
increases_quantity of
|
Hif1a
|
by stabilising Hif1alpha even under normoxic conditions
|
|
| 35050 |
response to hypoxia
|
|
increases_quantity of
|
HSC (Tie2+KSL)
|
in the bone marrow
|
in vivo
|
| 35051 |
response to hypoxia
|
|
increases_quantity of
|
HSC (CD150+CD48-CD41-KSL)
|
in the bone marrow
|
in vivo
|
| 35054 |
HSC (CD34-KSL)
|
|
increases_expression of
|
Hif1a
|
in comparison to ST-HSC (CD34+KSL)
|
|
| 35076 |
response to hypoxia
|
|
decreases_activity of
|
Egln1
|
|
|
| 35077 |
Egln1
|
|
decreases_quantity of
|
Hif1a
|
by hydroxylation of Hif1alpha resulting in increased proteasomal degradation of Hif1alpha
|
|
| 35079 |
Egln1
|
|
increases_activity of
|
Vhl
|
by hydroxylation of Hif1alpha
|
|
| 35083 |
Hif1a
|
|
increases_activity of
|
repopulation >16 weeks
|
|
in vivo
|
| 35084 |
Hif1a
|
|
decreases_expression of
|
Cdkn2a
|
in HSC (KSL)
|
|
| 35086 |
Hif1a
|
|
increases_activity of
|
self-renewal
|
|
in vivo
|
| 35093 |
Hif1a
|
|
decreases_activity of
|
cell cycle
|
in LT-HSC (CD34-KSL)
|
in vivo
|
| 35094 |
Vhl
|
|
increases_activity of
|
cell cycle
|
in LT-HSC (CD34-KSL); In Vhl-deficient mice Hif1a is stabilized.
|
in vivo
|
| 35095 |
Hif1a
|
|
increases_activity of
|
quiescence
|
in LT-HSC (CD34-KSL)
|
in vivo
|
| 35096 |
Vhl
|
|
decreases_activity of
|
quiescence
|
in LT-HSC (CD34-KSL); In Vhl-deficient mice Hif1a is stabilized.
|
in vivo
|
| 35097 |
Hif1a
|
|
decreases_quantity of
|
Reactive oxygen species
|
in LT-HSC (CD34-KSL)
|
in vivo
|
|
20804974
|
|
3,667
|
| 35098 |
HSC (LRC)
|
|
interacts (colocalizes) with
|
sinusoidal endothelium (fibronectin+)
|
|
in vivo
|
| 35101 |
response to hypoxia
|
|
increases_quantity of
|
HSC (LRC)
|
|
in vivo
|
| 36327 |
HSC (LRC)
|
|
increases_activity of
|
quiescence
|
|
in vivo
|
|
18047833
|
|
3,687
|
| 35431 |
Ptgs2
|
|
decreases_quantity of
|
Reactive oxygen species
|
by inhibiting Akt signaling
|
in vivo
|
| 35450 |
Prostaglandin E2
|
|
decreases_quantity of
|
Reactive oxygen species
|
in LT-HSC (CD34-KSL); in a manner dependent on the kinase Akt
|
in vitro
|
|
22983360
|
|
3,721
|
| 36167 |
Meis1
|
|
increases_quantity of
|
HSC (CD150+CD48-KSL)
|
by reducing oxidative stress conditions. Steady-state hematopoiesis is sustained even in the absence of Meis1.
|
in vivo
|
| 36179 |
Meis1
|
|
increases_activity of
|
repopulation >16 weeks
|
of HSC (CD150+CD48-KSL)
|
in vivo
|
| 36180 |
Meis1
|
|
increases_activity of
|
self-renewal
|
of HSC (CD150+CD48-KSL)
|
in vivo
|
| 36181 |
Meis1
|
|
increases_activity of
|
quiescence
|
of HSC (CD150+CD48-KSL)
|
in vivo
|
| 36182 |
Meis1
|
|
decreases_activity of
|
cell cycle
|
of HSC (CD150+CD48-KSL)
|
in vivo
|
| 36183 |
Meis1
|
|
decreases_quantity of
|
Reactive oxygen species
|
in HSC (CD150+CD48-KSL); by increasing the amount of hypoxia-response regulator Hif1alpha
|
in vivo
|
| 36225 |
Meis1
|
|
increases_expression of
|
Hif1a
|
in BMC (Lin-)
|
|
| 36229 |
Hif1a
|
|
decreases_activity of
|
response to oxidative stress
|
|
|
| 36231 |
Hif1a
|
|
decreases_quantity of
|
Reactive oxygen species
|
|
|
| 36236 |
Meis1
|
|
decreases_activity of
|
response to oxidative stress
|
in BMC (Lin-); by increasing the amount of hypoxia-response regulator Hif1alpha
|
|
|
23091297
|
|
3,727
|
| 36243 |
Bmi1
|
|
increases_quantity of
|
HSC (CD34-KSL)
|
under oxidative stress conditions
|
in vitro
|
| 36244 |
Bmi1
|
|
increases_activity of
|
self-renewal
|
if Bmi1 is overexpressed in CD34-KSL cells
|
in vivo
|
| 36245 |
Reactive oxygen species
|
|
decreases_quantity of
|
HSC (CD34-KSL)
|
|
in vitro
|
| 36246 |
Bmi1
|
|
decreases_activity of
|
response to oxidative stress
|
if Bmi1 is overexpressed in CD34-KSL cells. Unexpectedly, overexpression of Bmi1 has no effect on intracellular ROS level.
|
in vitro
|
|
22606246
|
|
3,729
|
| 36250 |
HSC (KSL)
|
|
increases_expression of
|
Nfe2l2
|
in comparison to committed myeloid (Kit+Sca1-Lin-) and lymphoid (Kit(lo)Sca1+Lin-) progenitors
|
|
| 36258 |
Nfe2l2
|
|
increases_activity of
|
repopulation >16 weeks
|
of HSC (KSL) cells
|
in vivo
|
| 36261 |
Nfe2l2
|
|
increases_activity of
|
repopulation, myeloid-biased
|
in HSC (CD34-CD150+KSL)
|
in vivo
|
| 36265 |
Nfe2l2
|
|
decreases_activity of
|
response to oxidative stress
|
|
in vitro
|
|
22039262
|
|
3,732
|
| 36299 |
Atm
|
|
increases_activity of
|
repopulation >16 weeks
|
of KSL cells; through reduction of ROS level and concomitant reduction of p16(Ink4a) level
|
in vivo
|
| 36300 |
Atm
|
|
decreases_quantity of
|
Reactive oxygen species
|
in KSL cells
|
in vivo
|
| 36301 |
Atm
|
|
decreases_activity of
|
response to oxidative stress
|
in KSL cells
|
in vivo
|
| 36304 |
Reactive oxygen species
|
|
increases_expression of
|
Cdkn2a
|
in KSL cells
|
in vitro
|
| 36305 |
Reactive oxygen species
|
|
increases_expression of
|
Cdkn2a
|
in KSL cells
|
in vitro
|
| 43053 |
Atm
|
|
affects_activity of
|
DNA damage checkpoint
|
|
|
|
15496926
|
|
3,793
|
| 37443 |
Ptpmt1
|
|
is localized in
|
mitochondrion
|
Ptpmt1 is localized to the mitochondrial inner membrane.
|
|
| 37446 |
HSC (CD150+CD48-CD135-KSL)
|
|
increases_expression of
|
Ptpmt1
|
in comparison to Lin+ and mature cells
|
|
| 37453 |
Ptpmt1
|
|
decreases_quantity of
|
HSC (CD150+CD48-CD135-KSL)
|
Depletion of PtpMt1 results in an expansion of the stem cell pool in the BM.
|
in vivo
|
| 37458 |
Ptpmt1
|
|
increases_activity of
|
hematopoietic stem cell differentiation
|
|
in vitro
|
| 37459 |
Ptpmt1
|
|
increases_activity of
|
repopulation >16 weeks
|
|
in vivo
|
| 37460 |
Ptpmt1
|
|
increases_activity of
|
self-renewal
|
|
in vivo
|
| 37461 |
Ptpmt1
|
|
increases_activity of
|
quiescence
|
|
in vivo
|
|
23290137
|
|
3,798
|
| 37746 |
Map3k5
|
|
increases_activity of
|
Mapk14
|
if Ask1 (Map3k5) has been induced by H2O2
|
|
| 37748 |
Reactive oxygen species
|
|
increases_activity of
|
Map3k5
|
|
|
|
16565722
|
|
3,800
|
| 37772 |
Reactive oxygen species
|
|
decreases_quantity of
|
Cdh2
|
in HSC (KSL)
|
in vitro
|
| 37780 |
Reactive oxygen species
|
|
decreases_quantity of
|
HSC (SP,KSL)
|
only transiently
|
in vivo
|
|
17897629
|
|
3,849
|
| 38632 |
Hif1a
|
|
increases_expression of
|
Cxcl12
|
|
|
| 38633 |
Hif1a
|
|
increases_expression of
|
Angpt2
|
|
|
| 38634 |
Hif1a
|
|
increases_expression of
|
Kitl
|
|
|
| 38635 |
Hif1an
|
|
decreases_activity of
|
Hif1a
|
|
|
| 38636 |
Mmp14
|
|
decreases_quantity of
|
Hif1an
|
in MS-5 stromal cells
|
|
| 38642 |
Mmp14
|
|
increases_activity of
|
Hif1a
|
in MS-5 stromal cells, by inhibiting FIH (Hif1an) activity
|
|
|
22544701
|
|
3,881
|
| 39152 |
Reactive oxygen species
|
|
increases_activity of
|
Nfe2l2
|
|
|
| 39153 |
Nfe2l2
|
|
decreases_activity of
|
response to oxidative stress
|
by controlling the expression of genes involved in the detoxication of reactive oxidants
|
|
|
23434824
|
|
4,004
|
| 41097 |
Hif1a
|
|
decreases_activity of
|
oxidative phosphorylation
|
in LT-HSCs
|
|
| 41108 |
HSC (CD34-CD135-KSL)
|
|
decreases_activity of
|
oxidative phosphorylation
|
|
|
| 41112 |
Hif1a
|
|
increases_activity of
|
glycolytic process
|
in LT-HSCs
|
|
| 41113 |
Hif1a
|
|
increases_expression of
|
Pdk2
|
in LT-HSCs
|
|
| 41114 |
Hif1a
|
|
increases_expression of
|
Pdk4
|
in LT-HSCs
|
|
|
23290136
|
|
4,125
|
| 42485 |
Bmi1
|
|
decreases_quantity of
|
Reactive oxygen species
|
in KSL cells and thymocytes
|
in vivo
|
| 42487 |
Bmi1
|
|
decreases_quantity of
|
Reactive oxygen species
|
in LT-HSC (CD150+CD48-CD41-KSL), due to impaired mitochondrial function
|
in vivo
|
| 42490 |
Bmi1
|
|
increases_activity of
|
cellular response to DNA damage stimulus
|
in thymocytes
|
in vivo
|
|
19404261
|
HSC